Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03891264 · ClinicalTrials.gov registry record · Phase 4
Investigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
NCT03891264: Clinical Trial Phase 4 study, sponsored by Massachusetts General Hospital.
NCT03891264 is a Phase 4 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 7 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03891264, a Phase 4 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
Study Summary
In this research, the study team will use brain imaging to evaluate the presence of neuroinflammation in the brains and spinal cords of patients with low back pain, and whether CBD effects levels of neuroinflammation. The efficacy of CBD use for low back pain treatment will also be evaluated by observing whether CBD administration will reduce neuroinflammation and low back pain symptoms.
Primary Outcome
The investigators will test for the presence of a significant treatment effect in the brain \[11C\]PBR28 signal.
Interventions
- DRUG Cannabidiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-11-13 |
| Est. Completion | 2020-11-23 |
| Phase | Phase 4 |
Why NCT03891264 stopped before completion
NCT03891264 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Cannabidiol is the first listed.
NCT03891264 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03891264 about?
NCT03891264 is a clinical study titled "Investigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain". In this research, the study team will use brain imaging to evaluate the presence of neuroinflammation in the brains and spinal cords of patients with low back pain, and whether CBD effects levels of neuroinflammation. The efficacy of CBD use for low back pain treatment will also be evaluated by obse...
What is the current status of trial NCT03891264?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2019-11-13. Estimated completion is 2020-11-23.
What interventions are being tested in trial NCT03891264?
The interventions under investigation include: Cannabidiol (DRUG).
Who is sponsoring clinical trial NCT03891264?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03891264's enrollment target sits among peer trials
7 1981st of 2000 higher than 18 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI